High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
about
Analysis of Microarray Data on Gene Expression and Methylation to Identify Long Non-coding RNAs in Non-small Cell Lung CancerA three-protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease.High expression of KPNA2 defines poor prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletionHOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomyTargeting nuclear transporters in cancer: Diagnostic, prognostic and therapeutic potential.Low cytoplasmic and nuclear KPNA2 expression in radiotherapy-treated head and neck squamous cell cancer is associated with an adverse outcome.MicroRNA-567 dysregulation contributes to carcinogenesis of breast cancer, targeting tumor cell proliferation, and migration.Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent copy number variation in IPO11 and prognostic significance of importin-11 overexpression on poor survival.KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation.Qualitative and Quantitative Requirements for Assessing Prognostic Markers in Prostate Cancer.Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins.Suppression of Kpnβ1 expression inhibits human breast cancer cell proliferation by abrogating nuclear transport of Her2.The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
P2860
Q31142542-900BE1C6-3F6A-4227-A839-C2BBDA6AA335Q34998516-8A4AF9A7-03C6-4C57-8BB6-4EB63AF7F997Q35609624-FCA45D26-3003-4CFA-A2D8-D670A144370CQ35706611-4594E103-BC6D-4E51-B69A-6A42E31EB285Q35828702-58406621-4174-4FDB-B19B-56BEBE23B455Q35955008-363115E9-C7F8-4C84-9D4C-065ADCC2DF6AQ36511735-C459193E-99A5-4A2A-BF9E-2E4BC61D9959Q37590613-C114E4F9-666E-4591-95BE-17AF089F2433Q37688998-845A37A8-EF35-4C0B-B34C-395B9B349F86Q38984603-46ED9F30-77F7-41B5-944D-8656B2815433Q39417832-C0EF87CC-D5C0-459F-BFF6-E4ACDFBE7BE7Q41091924-705F9E65-F8E0-4DF6-BE3D-F39EBE94A31AQ47282308-45173270-7771-4AEA-A331-F5EDC3681AC4Q53067309-F1B7A8CD-BC39-40CB-8434-F2CB250F429D
P2860
High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
High nuclear karyopherin α 2 e ...... ated by radical prostatectomy.
@en
High nuclear karyopherin α 2 e ...... ated by radical prostatectomy.
@nl
type
label
High nuclear karyopherin α 2 e ...... ated by radical prostatectomy.
@en
High nuclear karyopherin α 2 e ...... ated by radical prostatectomy.
@nl
prefLabel
High nuclear karyopherin α 2 e ...... ated by radical prostatectomy.
@en
High nuclear karyopherin α 2 e ...... ated by radical prostatectomy.
@nl
P2093
P2860
P1433
P1476
High nuclear karyopherin α 2 e ...... ated by radical prostatectomy.
@en
P2093
Claudia Hube-Magg
Georg Salomon
Guido Sauter
Hans Heinzer
Hüseyin Sirma
Jakob R Izbicki
Karolina Jedrzejewska
Katharina Grupp
Kristina Prien
Lia Burkhardt
P2860
P2888
P304
P356
10.1038/MODPATHOL.2013.127
P50
P577
2013-07-26T00:00:00Z
P5875
P6179
1022229777